Yatharth Hospital & Trauma Care Services said on 17 September 2026 that Advent International will invest ₹3,150 crore for a 24.9% stake, sending its shares to a record high on the NSE and BSE.
Advent’s ₹3,150 Crore Deal: How the Investment is Structured
Yatharth Hospital told stock exchanges that its board has approved a preferential issue of equity shares and warrants to Rasmalai Limited, a Cyprus-based investment vehicle linked to Advent International.
Once complete, this will give Advent a 24.9% minority stake (24.87% of post-issue equity, to be precise) in the Noida-based hospital chain. The promoter Tyagi family will remain the largest shareholder.
The board also approved raising Yatharth’s authorised share capital from ₹115 crore to ₹150 crore to allow the new shares to be issued.
| Deal Element | Detail |
|---|---|
| Investor | Advent International (via Rasmalai Limited, Cyprus) |
| Investment size | ₹3,150 crore |
| Resulting stake | 24.9% (minority) |
| Warrants | Up to 1,89,47,664, each convertible into one equity share |
| Warrant price | ₹985.17 per warrant |
| Payment terms | 25% upfront, 75% payable on exercise |
| Approval needed | Shareholders, via a special resolution at an EGM |
A warrant here simply means a right to buy a share later at a fixed price. Because 75% of the payment is linked to Advent exercising these warrants over time, the full ₹3,150 crore will flow into Yatharth in stages rather than all at once. The deal still needs shareholder approval at an Extraordinary General Meeting (EGM) and is subject to other customary closing conditions, so a final completion date has not been given.
Yatharth Hospital Shares Hit an All-Time High
The announcement moved the stock sharply on Thursday. On the NSE, Yatharth Hospital shares climbed as much as 8.6% to an all-time high of ₹1,067. On the BSE, they rose as much as 8.37% to a record ₹1,065.
Investors who want to track a stock like this in real time, or hold shares once they decide to invest, need a demat account and a trading account. Price-sensitive news such as this deal is easiest to follow through an online trading platform that shows live NSE and BSE quotes.
From Takeover Talks to a Minority Stake
This deal has a longer backstory. In late August 2026, media reports said Advent International and Blackstone-backed Aster DM Quality Care were in talks to buy a controlling stake in Yatharth, a deal that would have triggered an open offer for public shareholders under SEBI’s takeover rules. At the time, Yatharth denied being party to any sale discussions, and Blackstone said it was not evaluating any such deal.
Then, on 15 September 2026, it was reported that Yatharth was in talks with Advent alone to raise up to ₹3,000 crore in two tranches, with a possible stake of 20-24%.
Thursday’s definitive agreement is different from both of those earlier reports. It is a primary capital infusion of ₹3,150 crore for a 24.9% minority stake, not a sale of a controlling stake by the promoters.
Where the Money Will Go
Yatharth currently runs nine hospitals with about 2,800 operational beds across Noida, Greater Noida, Faridabad and Jhansi-Orchha. The company has said the fresh capital will support plans to expand capacity to more than 5,000 beds over the next three years, along with investment in robotics, oncology and transplant programmes.
Pankaj Patwari, Managing Director at Advent, said the investment reflects the firm’s long-term commitment to India’s healthcare sector, which it sees entering “a decade of structural growth” as access and quality improve. Yatharth Whole-time Director Yatharth Tyagi said Advent would bring healthcare expertise and a value-creation approach to help the company’s next phase of growth.
Part of a Bigger Push into Indian Hospitals
Global private equity money has been flowing into Indian healthcare through 2026. In August, KKR agreed to acquire Swedish firm Medicover’s India hospital business for an enterprise value of about ₹13,188 crore. Blackstone had earlier bought a controlling stake in Hyderabad’s CARE Hospitals, and BPEA EQT picked up a majority stake in fertility-services chain Indira IVF.
Yatharth’s own numbers help explain the investor interest. For the quarter ended June 2026, consolidated revenue rose 51% year-on-year to ₹392.70 crore, EBITDA grew 39% to ₹91.7 crore, and profit after tax was up 8% at ₹45.4 crore. Average revenue per occupied bed rose 7% to ₹34,758.
Investments in the stock market are subject to market risks. This article is for information only and is not investment advice.
Leave a Reply